Is Autologous Stem Cell Transplant Still Standard of Care in Myeloma? New Data from EHA 2026

Is Autologous Stem Cell Transplant Still Standard of Care in Myeloma? New Data from EHA 2026
Arlocabtagene Autoleucel (Arlo-Cel): Promising GPRC5D CAR-T Results in Relapsed Myeloma | EHA 2026
CAR-T vs Bispecifics — Which Performs Better in Myeloma After Initial BCMA Therapy Fails? | #EHA2026
A New Way to Deliver Isatuximab in Myeloma: Safety Insights on the On-Body Injector (OBI) | #EHA2026
BMS-986453 : A Next-Generation Dual-Target CAR-T Attacking BCMA + GPRC5D in Myeloma | #EHA2026
MajesTEC-4 / EMN30 Trial: Is Teclistamab the Future of Myeloma Maintenance After Transplant? | EHA26
Understanding Clinical Trials and the Financial Side of Clinical Trials
Why is diversity and inclusion important in clinical trials?
LINKER-MM1: Linvoseltamab Shows Promise Across High-Risk Myeloma | EHA 2026
Beyond CRS & ICANS: Insights Into Delayed Neurotoxicity After BCMA CAR-T Therapy in Myeloma | #EHA26
Can Taste Loss Be Managed? TALISMAN Study Shares New Answers for Talquetamab Patients | EHA 2026
Top Myeloma Updates from EHA 2026: New Therapies,Trials & Emerging Treatments | EHA 2026
TRIlogy-4: Ramantamig’s Triple Target Attack on Myeloma—BCMA, GPRC5D, and CD3 #EHA2026
SUCCESSOR-2 Trial: Mezigdomide Triplet Shows Powerful Results in Relapse/Refractory Multiple Myeloma
How to Protect Your Medical Records and Insurance From Theft: Being Your Own Private Eye